Article Text

PDF

P2.126 Kaposi´S Sarcoma Patient Profile in the Cohort of the German Competence Netzwork HIV/AIDS
  1. R E Scheitz1,
  2. S Esser2,3,
  3. N H Brockmeyer1,3,4,
  4. A Moll5,3,
  5. S Dupke6,3,
  6. M Rausch7,3,
  7. H Rasokat8,3,
  8. C Michalik9,3,
  9. S Scholten10,3,
  10. A V Potthoff1,3
  1. 1Clinic for Dermatology, Venerology and Allergology, Ruhr-Universität Bochum, Bochum, Germany
  2. 2Clinic for Dermatology and Venerology, University Clinic Essen, Essen, Germany
  3. 3Competence Network for HIV/AIDS, Bochum, Germany
  4. 4German STI-Society (DSTIG), Bochum, Germany
  5. 5Practice Center Kaiserdamm, Berlin, Germany
  6. 6Private practise Driesener Strasse, Berlin, Germany
  7. 7Doctors Center Nollendorfplatz, Berlin, Germany
  8. 8Clinic and Polyclinic for Dermatology and Venerology, University Clinic Cologne, Cologne, Germany
  9. 9Centre for Clinical Trials, Cologne, Germany
  10. 10Private practise Hohenstaufenring, Cologne, Germany

Abstract

Background The aim of this study is the acquisition and description of patients with HIV-associated Kaposi-sarcoma (KS) from the cohort database of the competence network for HIV/AIDS.

Patients and Methods Data from patients with diagnosis of KS from 9 centres of the competence network for HIV/AIDS were evaluated. The baseline characteristics at the time of the initial KS diagnosis were described. Recurrence and survival probabilities were estimated by means of Kaplan-Meier curves. The influence factors for survival were analysed with multiple Cox regression models. As potential risk factors for the mortality risk the CD4- and CD8 cell count, HIV-viral load value, antiretroviral therapy (ART), chemotherapy and the patient’s age were evaluated.

Results In the period of 1987–2011 KS was diagnosed in 222 study participants, 97.7% were men and 2.3% women. The most common HIV-transmission risk was MSM (88.3%). The median age was 38.5 years (min. 23.4; max. 76.8). 70.5% of the patients showed exclusively cutaneus presentation. The median value of HIV viral load was 37,000 copies per ml at the initial diagnosis of KS. 55.5% of the patients had a CD4 cell count under 200/µl. A KS therapy was documented for 198 patients. The 222 study participants were clustered according their therapies; ART only and ART in combination with other treatments, e.g. liposomal doxorubicin or other chemotherapeutic regimen, local excision, radiation and/or interferon-alpha. It was shown that about 80% of the patients had no recurrence after the therapies and 18 patients died. The 5 and 10-year survival probabilities were 96.8% and 91.3%. In addition it was shown by the Cox-model that patients with higher CD4 and patients without ART before KS diagnosis had a significant lower mortality risk.

Conclusion A low CD4 cell count at KS diagnosis is an important predictor for mortality.

  • HIV
  • Kaposi’s sarcoma
  • Patient profile

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.